Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

1.7K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
1.7K
Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

4.5K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.5K
iPS Cell Differentiation01:22

iPS Cell Differentiation

2.2K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.2K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

3.8K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
3.8K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

4.8K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.8K
Stem Cell Culture01:17

Stem Cell Culture

4.5K
Stem cell research aims to find ways to use stem cells to regenerate and repair cellular damage. Over time, most adult cells undergo the wear and tear of aging and lose their ability to divide and repair themselves. Stem cells do not display a particular morphology or function. Adult stem cells, which exist as a small subset of cells in most tissues, keep dividing and can differentiate into a number of specialized cells generally formed by that tissue. These cells enable the body to renew and...
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Type II CDK6 Degrader Enables Cellular Targeting beyond the Limits of Type II Inhibition.

Journal of the American Chemical Society·2026
Same author

Isolation of postnatal human neural stem cells.

bioRxiv : the preprint server for biology·2026
Same author

Clonal Hematopoiesis of Indeterminate Potential and Kidney Failure in Chronic Kidney Disease: An East Asian Cohort Study.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same author

Somatic mutations reveal the ontogeny of human microglia.

bioRxiv : the preprint server for biology·2026
Same author

<i>Ppm1d</i> Clonal Hematopoiesis Does Not Promote Atherosclerosis in Murine Models.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same author

Clonal hematopoiesis in lung adenocarcinoma pathogenesis.

JCI insight·2026
Same journal

Circadian Homeostasis of Liver Metabolism Suppresses Hepatocarcinogenesis.

Cancer cell·2026
Same journal

Vascular RhoJ Is an Effective and Selective Target for Tumor Angiogenesis and Vascular Disruption.

Cancer cell·2026
Same journal

Intratumoral B cells under stress.

Cancer cell·2026
Same journal

Chronic stress unleashes an intratumor phage-fibroblast-B cell circuit to promote tumor growth.

Cancer cell·2026
Same journal

Molecular phenotypes and spatial archetypes: A new framework for cancer-associated fibroblasts.

Cancer cell·2026
Same journal

OpenIO: An open framework for AI-native immunotherapy.

Cancer cell·2026
See all related articles

Related Experiment Video

Updated: Apr 28, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.0K

MDS is a stem cell disorder after all.

Siddhartha Jaiswal1, Benjamin L Ebert2

  • 1Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

Cancer Cell
|June 18, 2014
PubMed
Summary
This summary is machine-generated.

Myelodysplastic syndromes (MDS) are now formally proven to originate in stem cells. Driver mutations in MDS are definitively located within stem cells, confirming a long-held hypothesis.

More Related Videos

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

10.8K
Transient Treatment of Human Pluripotent Stem Cells with DMSO to Promote Differentiation
06:55

Transient Treatment of Human Pluripotent Stem Cells with DMSO to Promote Differentiation

Published on: July 17, 2019

14.1K

Related Experiment Videos

Last Updated: Apr 28, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.0K
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

10.8K
Transient Treatment of Human Pluripotent Stem Cells with DMSO to Promote Differentiation
06:55

Transient Treatment of Human Pluripotent Stem Cells with DMSO to Promote Differentiation

Published on: July 17, 2019

14.1K

Area of Science:

  • Hematology
  • Cancer Biology
  • Stem Cell Research

Background:

  • Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
  • MDS is characterized by ineffective hematopoiesis and a high risk of transformation to acute myeloid leukemia.
  • The origin of MDS in stem cells has been long presumed but lacked definitive proof.

Purpose of the Study:

  • To provide rigorous formal proof that Myelodysplastic syndromes (MDS) originate in stem cells.
  • To identify the specific cell type within the hematopoietic system where driver mutations in MDS occur.

Main Methods:

  • Utilizing advanced techniques to phenotype and genotype cells from MDS patients.
  • Analyzing driver mutations within distinct stem and progenitor cell populations.

Main Results:

  • Driver mutations in Myelodysplastic syndromes (MDS) were definitively located in cells exhibiting a stem cell phenotype.
  • This study provides the first rigorous formal proof of MDS as a stem cell disorder.

Conclusions:

  • The findings confirm that Myelodysplastic syndromes (MDS) are indeed stem cell disorders.
  • This definitive proof has significant implications for understanding MDS pathogenesis and developing targeted therapies.